Pasithea Therapeutics Corp.

NasdaqCM KTTA

Pasithea Therapeutics Corp. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024

Pasithea Therapeutics Corp. Operating Cash Flow is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Operating cash flow is cash generated from the company’s regular business operations.

Pasithea Therapeutics Corp. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -13.76 M, a -26.54% change year over year.
Pasithea Therapeutics Corp. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -10.87 M.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

NasdaqCM: KTTA

Pasithea Therapeutics Corp.

CEO	Dr. Tiago Reis Marques M.D., Ph.D.
IPO Date	Sept. 15, 2021
Location	United States
Headquarters	1111 Lincoln Road
Employees	8
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Key trends

Past 5 years